SPOKANE, Wash.--(BUSINESS WIRE)--Signature Genomic Laboratories’ flagship microarray, the SignatureChip®, covers regions of the human genome that were known and recently published to be associated with susceptibility to schizophrenia.
SPOKANE, Wash.--(BUSINESS WIRE)--Signature Genomic Laboratories’ flagship microarray, the SignatureChip®, covers regions of the human genome that were known and recently published to be associated with susceptibility to schizophrenia.
